
|Articles|August 11, 2016
FDA Grants Nivolumab Priority Review in Head and Neck Cancer
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in recurrent or metastatic head and neck cancer, based on results of the CheckMate-141 study.
The study found that nivolumab improved overall survival (7.5 vs 5.1 months) over investigator’s choice.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer
2
Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer
3
FDA Traditionally Approves Selpercatinib in RET+ Solid Tumors
4
Subcutaneous Isatuximab Approval Expands Options in Multiple Myeloma
5


























































